Tuberculosis and Respiratory Diseases

  • 제67권4호
  • /
  • Pages.351-355
  • /
  • 2009
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

JAK2 돌연변이를 동반한 폐색전증 1예

A Case of Pulmonary Thromboembolism with JAK2 Mutation

  • 김진진 (가톨릭대학교 의과대학 내과학교실) ;
  • 권순석 (가톨릭대학교 의과대학 내과학교실) ;
  • 이현정 (가톨릭대학교 의과대학 내과학교실) ;
  • 이혜연 (가톨릭대학교 의과대학 내과학교실) ;
  • 정명희 (가톨릭대학교 의과대학 진단방사선학교실) ;
  • 김용현 (가톨릭대학교 의과대학 내과학교실)
  • Kim, Jin-Jin (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kwon, Soon-Seog (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Hyun-Jeong (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Hea-Yon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Jeong, Myung-Hee (Department of Diagnostic Radiology, The Catholic University of Korea College of Medicine) ;
  • Kim, Yong-Hyun (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 투고 : 2009.07.29
  • 심사 : 2009.08.31
  • 발행 : 2009.10.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The incidence of pulmonary thromboembolism increases with age. The risk factors of pulmonary thromboembolism include surgery, malignancy, obesity, lupus anticoagulants, and vascular conditions such as deep vein thrombosis. Thromboembolism in younger patients or in unusual locations, the possibility of primary thrombophilic conditions should be considered. Primary thrombophilic states include myeloproliferative disorders (MPD). JAK2 V617F mutation is found commonly in patients diagnosed with MPD, in 90~95% of polycythemia vera (PV) and in 50~60% of essential thrombocytosis (ET) patients. Sometimes the JAK2 V617F mutation is found in cases without MPD. The relationship between JAK2 V617F mutation and thrombosis has not been defined. Recently, clinical evidence suggests that this mutation may be variably associated with thrombosis. We present one case of pulmonary thromboembolism in a young patient, who was positive for the JAK2 V617F mutation and did not have MPD.

키워드

참고문헌

  1. Silverstein MD, Heit JA, Mohr DN, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93 https://doi.org/10.1001/archinte.158.6.585
  2. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology 2005;1:1-12
  3. Wong RS, Cheng CK, Chan NP, Cheng SH, Wong WS, Lau KM, et al. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia. Br J Haematol 2008;141:902-4 https://doi.org/10.1111/j.1365-2141.2008.07127.x
  4. The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990;43:703-9 https://doi.org/10.1136/jcp.43.9.703
  5. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358:1037-52 https://doi.org/10.1056/NEJMra072753
  6. Gomez K, Laffan MA. Hunting for the mutation in inherited thrombophilia. Blood Coagul Fibrinolysis 2004;15:125-7 https://doi.org/10.1097/00001721-200403000-00002
  7. D'Angelo A, Della Valle P, Crippa L, Fattorini A, Pattarini E, Vigano D'Angelo S. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica 2002;87:1074-80
  8. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8 https://doi.org/10.1038/nature03546
  9. Austin SK, Lambert JR. The JAK2 V617F mutation and thrombosis. Br J Haematol 2008;143:307-20 https://doi.org/10.1111/j.1365-2141.2008.07258.x
  10. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006;1:240-5
  11. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, et al. JAK2 (V617F): prevalence in a large Chinese hospital population. Blood 2007;109:339-42 https://doi.org/10.1182/blood-2006-03-009472
  12. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007;5:55-61
  13. Rossi D, Cresta S, Destro T, Vendramin C, Bocchetta S, De Paoli L, et al. JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. Br J Haematol 2007;138:813-4 https://doi.org/10.1111/j.1365-2141.2007.06715.x
  14. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859-61 https://doi.org/10.1111/j.1538-7836.2007.02384.x
  15. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-14 https://doi.org/10.1111/j.1538-7836.2007.02424.x